本帖最后由 老马 于 2013-3-13 13:43 编辑 ! V, y) z2 \4 }8 \8 g$ ?
' M& @5 ~0 X1 e% m. d6 A% V
健择（吉西他滨）+顺铂+阿瓦斯汀
4 \% S( F% j7 |' n0 b: l Gemzar +Cisplatin + Avastin# m* o: @- C8 {7 ]0 @2 y
http://annonc.oxfordjournals.org/content/21/9/1804.full6 d$ N7 e4 Q; C7 ?) M& k2 W
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- z6 a7 s: x* P4 l. }Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 5 t8 f4 v; N: b( O5 G2 X
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
/ i/ i1 k M3 C9 B& U! R" Q4 u
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 850)
! o6 {* ^: F$ r; B% w华为网盘附件：
' ^- Q7 l3 \+ v1 h: a2 M! I【华为网盘】ava.JPG
6 V/ `! Q# n2 j$ Z |
显身卡
